Physician profile
Joy C Commisso
NPI 1326293572
$2,192.96
in general payments reported to CMS, 2019-2025
28 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $295 · 2021: $32.81 · 2022: $168 · 2023: $25.00 · 2024: $56.27 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.68 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $686.46 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $200.33 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $176.05 | 2019-2022 | |
| Abbvie INC. | $157.79 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.17 | 2019-2020 | |
| Pfizer INC. | $110.14 | 2019-2025 | |
| Lilly USA, LLC | $87.03 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $81.99 | 2019-2020 | |
| Amarin Pharma, INC. | $68.19 | 2019 | |
| Eisai INC. | $61.28 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $57.11 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.89 | 2022 | |
| Grifols USA, LLC | $38.17 | 2019 | |
| Inspire Medical Systems, INC. | $35.44 | 2025 | Inspire |
| Abbott Laboratories | $32.14 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $26.90 | 2025 | |
| Merck Sharp & Dohme LLC | $25.41 | 2019 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Oyster Point Pharma, INC. | $23.56 | 2024 | Ryzumvi, Tyrvaya |
| Phathom Pharmaceuticals, INC. | $17.20 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $17.03 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.68 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.65 | 2019 | |
| Mylan Specialty L.P. | $13.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.68 | 2019 | |
| Amgen INC. | $12.60 | 2019 | |
| Daiichi Sankyo INC. | $12.08 | 2019 | |
| Allergan, INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Commisso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.